SPX3,647.29-7.75 -0.21%
DIA291.30-1.42 -0.49%
IXIC10,829.50+26.58 0.25%

Apollomics To be Listed on Nasdaq Through Business Combination With Maxpro Capital Acquisition Corp.; Transaction Values Apollomics At Pre-Money Equity Value Of $899M

Apollomics Inc. ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. ("Maxpro") (NASDAQ:JMAC,  , JMACU,  , JMACW))))

Benzinga · 09/14/2022 08:33

Apollomics Inc. ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. ("Maxpro") (NASDAQ:JMAC,  , JMACU,  , JMACW))))) today announced a definitive agreement for a business combination (the "Transaction" or the "Business Combination") that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market ("Nasdaq"). The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker symbol "APLM."